Karina-Doris Vihta1, Nicole Stoesser2, Martin J Llewelyn3, T Phuong Quan4, Tim Davies4, Nicola J Fawcett2, Laura Dunn5, Katie Jeffery5, Chris C Butler6, Gail Hayward6, Monique Andersson5, Marcus Morgan5, Sarah Oakley5, Amy Mason2, Susan Hopkins7, David H Wyllie2, Derrick W Crook8, Mark H Wilcox9, Alan P Johnson10, Tim E A Peto4, A Sarah Walker4. 1. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; National Institute for Health Research (NIHR) Health Protection Research Unit on Healthcare Associated Infections and Antimicrobial Resistance, Oxford, UK. Electronic address: karina-doris.vihta@ccc.ox.ac.uk. 2. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. 3. Brighton and Sussex Medical School, University of Sussex, Falmer, UK. 4. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; National Institute for Health Research (NIHR) Health Protection Research Unit on Healthcare Associated Infections and Antimicrobial Resistance, Oxford, UK. 5. Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 6. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. 7. National Infection Service, Public Health England, Colindale, UK. 8. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; National Institute for Health Research (NIHR) Health Protection Research Unit on Healthcare Associated Infections and Antimicrobial Resistance, Oxford, UK; National Infection Service, Public Health England, Colindale, UK. 9. Healthcare Associated Infections Research Group, University of Leeds, Leeds, UK. 10. National Institute for Health Research (NIHR) Health Protection Research Unit on Healthcare Associated Infections and Antimicrobial Resistance, Oxford, UK; National Infection Service, Public Health England, Colindale, UK.
Abstract
BACKGROUND: Escherichia coli bloodstream infections are increasing in the UK and internationally. The evidence base to guide interventions against this major public health concern is small. We aimed to investigate possible drivers of changes in the incidence of E coli bloodstream infection and antibiotic susceptibilities in Oxfordshire, UK, over the past two decades, while stratifying for time since hospital exposure. METHODS: In this observational study, we used all available data on E coli bloodstream infections and E coli urinary tract infections (UTIs) from one UK region (Oxfordshire) using anonymised linked microbiological data and hospital electronic health records from the Infections in Oxfordshire Research Database (IORD). We estimated the incidence of infections across a two decade period and the annual incidence rate ratio (aIRR) in 2016. We modelled the data using negative binomial regression on the basis of microbiological, clinical, and health-care-exposure risk factors. We investigated infection severity, 30-day all-cause mortality, and community and hospital amoxicillin plus clavulanic acid (co-amoxiclav) use to estimate changes in bacterial virulence and the effect of antimicrobial resistance on incidence. FINDINGS: From Jan 1, 1998, to Dec 31, 2016, 5706 E coli bloodstream infections occurred in 5215 patients, and 228 376 E coli UTIs occurred in 137 075 patients. 1365 (24%) E coli bloodstream infections were nosocomial (onset >48 h after hospital admission), 1132 (20%) were quasi-nosocomial (≤30 days after discharge), 1346 (24%) were quasi-community (31-365 days after discharge), and 1863 (33%) were community (>365 days after hospital discharge). The overall incidence increased year on year (aIRR 1·06, 95% CI 1·05-1·06). In 2016, 212 (41%) of 515 E coli bloodstream infections and 3921 (28%) of 13 792 E coli UTIs were co-amoxiclav resistant. Increases in E coli bloodstream infections were driven by increases in community (aIRR 1·10, 95% CI 1·07-1·13; p<0·0001) and quasi-community (aIRR 1·08, 1·07-1·10; p<0·0001) cases. 30-day mortality associated with E coli bloodstream infection decreased over time in the nosocomial (adjusted rate ratio [RR] 0·98, 95% CI 0·96-1·00; p=0·03) group, and remained stable in the quasi-nosocomial (adjusted RR 0·98, 0·95-1·00; p=0·06), quasi-community (adjusted RR 0·99, 0·96-1·01; p=0·32), and community (adjusted RR 0·99, 0·96-1·01; p=0·21) groups. Mortality was, however, substantial at 14-25% across all hospital-exposure groups. Co-amoxiclav-resistant E coli bloodstream infections increased in all groups across the study period (by 11-18% per year, significantly faster than co-amoxiclav-susceptible E coli bloodstream infections; pheterogeneity<0·0001), as did co-amoxiclav-resistant E coli UTIs (by 14-29% per year; pheterogeneity<0·0001). Previous year co-amoxiclav use in primary-care facilities was associated with increased subsequent year community co-amoxiclav-resistant E coli UTIs (p=0·003). INTERPRETATION: Increases in E coli bloodstream infections in Oxfordshire are primarily community associated, with substantial co-amoxiclav resistance; nevertheless, we found little or no change in mortality. Focusing interventions on primary care facilities, particularly those with high co-amoxiclav use, could be effective in reducing the incidence of co-amoxiclav-resistant E coli bloodstream infections, in this region and more generally. FUNDING: National Institute for Health Research.
BACKGROUND: Escherichia coli bloodstream infections are increasing in the UK and internationally. The evidence base to guide interventions against this major public health concern is small. We aimed to investigate possible drivers of changes in the incidence of E coli bloodstream infection and antibiotic susceptibilities in Oxfordshire, UK, over the past two decades, while stratifying for time since hospital exposure. METHODS: In this observational study, we used all available data on E coli bloodstream infections and E coli urinary tract infections (UTIs) from one UK region (Oxfordshire) using anonymised linked microbiological data and hospital electronic health records from the Infections in Oxfordshire Research Database (IORD). We estimated the incidence of infections across a two decade period and the annual incidence rate ratio (aIRR) in 2016. We modelled the data using negative binomial regression on the basis of microbiological, clinical, and health-care-exposure risk factors. We investigated infection severity, 30-day all-cause mortality, and community and hospital amoxicillin plus clavulanic acid (co-amoxiclav) use to estimate changes in bacterial virulence and the effect of antimicrobial resistance on incidence. FINDINGS: From Jan 1, 1998, to Dec 31, 2016, 5706 E coli bloodstream infections occurred in 5215 patients, and 228 376 E coli UTIs occurred in 137 075 patients. 1365 (24%) E coli bloodstream infections were nosocomial (onset >48 h after hospital admission), 1132 (20%) were quasi-nosocomial (≤30 days after discharge), 1346 (24%) were quasi-community (31-365 days after discharge), and 1863 (33%) were community (>365 days after hospital discharge). The overall incidence increased year on year (aIRR 1·06, 95% CI 1·05-1·06). In 2016, 212 (41%) of 515 E coli bloodstream infections and 3921 (28%) of 13 792 E coli UTIs were co-amoxiclav resistant. Increases in E coli bloodstream infections were driven by increases in community (aIRR 1·10, 95% CI 1·07-1·13; p<0·0001) and quasi-community (aIRR 1·08, 1·07-1·10; p<0·0001) cases. 30-day mortality associated with E coli bloodstream infection decreased over time in the nosocomial (adjusted rate ratio [RR] 0·98, 95% CI 0·96-1·00; p=0·03) group, and remained stable in the quasi-nosocomial (adjusted RR 0·98, 0·95-1·00; p=0·06), quasi-community (adjusted RR 0·99, 0·96-1·01; p=0·32), and community (adjusted RR 0·99, 0·96-1·01; p=0·21) groups. Mortality was, however, substantial at 14-25% across all hospital-exposure groups. Co-amoxiclav-resistant E coli bloodstream infections increased in all groups across the study period (by 11-18% per year, significantly faster than co-amoxiclav-susceptible E coli bloodstream infections; pheterogeneity<0·0001), as did co-amoxiclav-resistant E coli UTIs (by 14-29% per year; pheterogeneity<0·0001). Previous year co-amoxiclav use in primary-care facilities was associated with increased subsequent year community co-amoxiclav-resistant E coli UTIs (p=0·003). INTERPRETATION: Increases in E coli bloodstream infections in Oxfordshire are primarily community associated, with substantial co-amoxiclav resistance; nevertheless, we found little or no change in mortality. Focusing interventions on primary care facilities, particularly those with high co-amoxiclav use, could be effective in reducing the incidence of co-amoxiclav-resistant E coli bloodstream infections, in this region and more generally. FUNDING: National Institute for Health Research.
Authors: Michihiko Goto; Amy M J O'Shea; Daniel J Livorsi; Jennifer S McDanel; Makoto M Jones; Kelly K Richardson; Brice F Beck; Bruce Alexander; Martin E Evans; Gary A Roselle; Stephen M Kralovic; Eli N Perencevich Journal: Clin Infect Dis Date: 2016-06-28 Impact factor: 9.079
Authors: Chris C Butler; Frank Dunstan; Margaret Heginbothom; Brendan Mason; Zoë Roberts; Sharon Hillier; Robin Howe; Stephen Palmer; Anthony Howard Journal: Br J Gen Pract Date: 2007-10 Impact factor: 5.386
Authors: Maurine A Leverstein-van Hall; Karola Waar; Jan Muilwijk; James Cohen Stuart Journal: J Antimicrob Chemother Date: 2013-06-13 Impact factor: 5.790
Authors: Iryna Schlackow; A Sarah Walker; Kate Dingle; David Griffiths; Sarah Oakley; John Finney; Ali Vaughan; Martin J Gill; Derrick W Crook; Tim E A Peto; David H Wyllie Journal: PLoS Med Date: 2012-07-31 Impact factor: 11.069
Authors: Teemu Kallonen; Hayley J Brodrick; Simon R Harris; Jukka Corander; Nicholas M Brown; Veronique Martin; Sharon J Peacock; Julian Parkhill Journal: Genome Res Date: 2017-07-18 Impact factor: 9.043
Authors: Christopher C Butler; Mandy Lau; David Gillespie; Eleri Owen-Jones; Mark Lown; Mandy Wootton; Philip C Calder; Antony J Bayer; Michael Moore; Paul Little; Jane Davies; Alison Edwards; Victoria Shepherd; Kerenza Hood; F D Richard Hobbs; Mina Davoudianfar; Heather Rutter; Helen Stanton; Rachel Lowe; Richard Fuller; Nick A Francis Journal: JAMA Date: 2020-07-07 Impact factor: 56.272
Authors: Muhanad Mohamed; Connie Clabots; Stephen B Porter; Tricia Bender; Paul Thuras; James R Johnson Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: Edward Goldstein; Derek R MacFadden; Zeynal Karaca; Claudia A Steiner; Cecile Viboud; Marc Lipsitch Journal: Int J Antimicrob Agents Date: 2019-03-06 Impact factor: 5.283
Authors: Lucy McDonnell; Alexander Gilkes; Mark Ashworth; Victoria Rowland; Timothy Hugh Harries; David Armstrong; Patrick White Journal: Gut Microbes Date: 2021 Jan-Dec